Latest News and Press Releases

STOCKHOLM, June 17, 2018. Karolinska Development's portfolio company Aprea Therapeutics presents continued positive development for the candidate drug APR-246 in patients with TP53 Mutant...

STOCKHOLM, June 17, 2018. Karolinska Development's portfolio company Aprea Therapeutics presents continued positive development for the candidate drug APR-246 in patients with TP53 Mutant...

STOCKHOLM, May 31, 2018. Karolinska Development's portfolio company Pharmanest AB has announced that it has entered into an exclusive agreement with Acerus Pharmaceuticals Corporation pertaining to...

STOCKHOLM, May 31, 2018. Karolinska Development's portfolio company Pharmanest AB has announced that it has entered into an exclusive agreement with Acerus Pharmaceuticals Corporation pertaining to...

STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science...

  STOCKHOLM, May 21, 2018. Karolinska Development's portfolio company Pharmanest AB announces the appointment of Helena Jansson as new Chief Executive Officer. Helena is an experienced life science...

STOCKHOLM den 26 april 2018. Vid Karolinska Developments årsstämma som hölls den 26 april 2018 beslutade aktieägarna, följande: Redovisning: beslutades att fastställa av resultaträkning och...

STOCKHOLM - April 26, 2018. At the Annual General Meeting of Karolinska Development AB held April 26, 2018, the following resolutions were passed: Profit and loss statement and the balance sheet: It...

STOCKHOLM - den 25 april 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari - mars 2018. Den fulla rapporten är tillgänglig på bolagets hemsida....

STOCKHOLM - 25 April 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report for the period January - March 2018. The full report is available on the Company's...